T. Rowe Price Investment Management’s RxSight RXST Stock Holding History

T. Rowe Price Investment Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-416	Closed	-$4K	–	950
2025 Q3	$4K	Buy	416 +84	+25%	+$737	﹤0.01%	803
2025 Q2	$5K	Sell	332 -719,486	-100%	-$10.8M	﹤0.01%	683
2025 Q1	$18.2M	Buy	719,818 +646,791	+886%	+$19.2M	0.01%	524
2024 Q4	$2.51M	Sell	73,027 -3,006	-4%	-$136K	﹤0.01%	588
2024 Q3	$3.76M	Sell	76,033 -112,994	-60%	-$5.79M	﹤0.01%	573
2024 Q2	$11.4M	Sell	189,027 -583,192	-76%	-$33.3M	0.01%	543
2024 Q1	$39.8M	Sell	772,219 -185,886	-19%	-$9.12M	0.02%	429
2023 Q4	$38.6M	Buy	958,105 +417,417	+77%	+$12.2M	0.03%	419
2023 Q3	$15.1M	Buy	+540,688	New	+$16.1M	0.01%	503

Other funds holding RXST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

T. Rowe Price Investment Management's RXST Position: Q4 2025 in Review

T. Rowe Price Investment Management sold out of RxSight (RXST) in Q4 2025, closing a stake of 416 shares — an estimated $4K sold.

T. Rowe Price Investment Management first reported a position in RXST in Q3 2023 and held it in 9 quarters. The position peaked at $39.8M in Q1 2024. 163 funds tracked by Wall St. Rank hold RXST as of Q4 2025.

T. Rowe Price Investment Management reported no remaining RxSight position as of Q4 2025 after selling out during the quarter.
T. Rowe Price Investment Management sold 416 RxSight shares in Q4 2025, an estimated $4K.
T. Rowe Price Investment Management first reported a position in RxSight in Q3 2023 and held it in 9 quarters.
T. Rowe Price Investment Management's RxSight position peaked at $39.8M in Q1 2024.
163 funds tracked by Wall St. Rank held RxSight as of Q4 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.